Class III — Low Risk

Low risk — use of or exposure to this product is not likely to cause adverse health consequences.

OraVerse (Phentolamine Mesylate) Injection Recalled by Septodont Inc. Due to Failed Impurities/Degradation: This recall has been initiated due...

Date: April 13, 2018
Company: Septodont Inc.
Status: Terminated
Source: FDA (Drug)

What You Should Do

Stop using this product immediately. Do not consume, use, or distribute it.

Return the product to the place of purchase for a full refund. If you have questions, contact Septodont Inc. directly.

Affected Products

OraVerse (Phentolamine Mesylate) Injection, 0.4 mg/1.7mL, packaged in a box of 10 cartridges of 0.4mg/1.7mL each, Rx only, Distributed by Septodont, Inc., Louisville, CO 80027, Made in Canada by Novocol Pharmaceutical of Canada, Inc., NDC 0362-0101-10

Quantity: 8509 boxes

Why Was This Recalled?

Failed Impurities/Degradation: This recall has been initiated due to an out of specification (OOS) result that was obtained for related substance (Phentolamide), a known degradation product impurity at the 15 month stability test point.

Where Was This Sold?

USA, Italy and France

About Septodont Inc.

Septodont Inc. has 2 total recalls tracked by RecallDetector.

Related Recalls

Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report